Blindness News and Research

RSS

Zeaxanthin reduces risk for AMD

St. Louis-based ZeaVision, LLC announced that three recent groundbreaking studies demonstrate that Zeaxanthin (zee-uh-zan-thin), the predominate protective pigment in the back of the eye, reduces the risk for Age-Related Macular Degeneration (AMD) and benefits the treatment of advanced AMD, a condition that destroys central vision and affects millions of Americans.

24 Oct 2011

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Embryonic stem cell therapy patents knocked back in Europe

The European Union's highest court ruled Tuesday that scientists cannot patent stem cell techniques that use human embryos for research, a decision some scientists said could threaten major medical advances if it prevents biotech companies from turning a profit.

20 Oct 2011

Topical corticosteroids show promise against bacterial corneal ulcers

A UCSF study gives hope to those suffering from severe cases of bacterial corneal ulcers, which can lead to blindness if left untreated. The use of topical corticosteroids in a randomized controlled trial was found to be neither beneficial nor harmful in the overall patient population in the study. However, it helped patients who had more serious forms of bacterial corneal ulcers, according to UCSF researchers.

19 Oct 2011

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.

19 Oct 2011

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration has approved its Investigational New Drug application for the Phase I/IIa clinical development of UshStat, a novel gene-based treatment for Usher syndrome type 1B.

18 Oct 2011

NIH grants support SUNY's neuroscience, pediatric pharmacology and vision research

The State University of New York has received two grants totaling more than $4.3 million from the National Institutes of Health (NIH) to support neuroscience and pediatric pharmacology and vision research as part of SUNY REACH, a collaborative research network of SUNY's four academic health centers and the College of Optometry.

15 Oct 2011

Action Medical Research announces grants to investigate conditions affecting babies, children

Action Medical Research - the leading UK-wide medical research charity dedicated to helping babies and children - has today announced grants worth more than £1.3 million for top researchers across the country.

13 Oct 2011

Researchers identify age-dependent beta cell proliferation pathway

As a person ages, the ability of their beta cells to divide and make new beta cells declines. By the time children reach the age of 10 to 12 years, the ability of their insulin-producing cells to replicate greatly diminishes. If these cells, called beta cells, are destroyed-as they are in type 1 diabetes-treatment with the hormone insulin becomes essential to regulate blood glucose levels and get energy from food.

13 Oct 2011

German stem cell scientist wins annual Young Investigator Award in Serbia

A young scientist who led research into the use of stem cells from hair follicles to treat the ocular surface disease has been named the winner of the Young Investigator Award by the journal Stem Cells.

12 Oct 2011

British scientist wins NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation (NYSCF) announced today that a British stem cell scientist working to cure blindness will be the first recipient of The New York Stem Cell Foundation - Robertson Prize in Stem Cell Research, a $200,000 prize awarded annually for extraordinary achievement in translational stem cell research.

12 Oct 2011

Study finds experimental vaccine protects monkeys from blinding trachoma

"An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health (NIH) study in monkeys," an NIH press release reports.

12 Oct 2011

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function.

12 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

UMass Amherst SPHHS wins HHS award to create Public Health Training Center

Training to improve the nation's public health system by strengthening the technical, scientific, managerial and leadership competence of current and future public health workers will soon be underway in Springfield, Holyoke, Pittsfield and the Berkshires, supported by a four-year, $2.5 million grant to the School of Public Health and Health Sciences (SPHHS) at the University of Massachusetts Amherst.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Logistic regression models identify risk factors for open angle glaucoma

Early detection and diagnosis of open angle glaucoma important so that treatment can be used in the early stages of the disease developing to prevent or avoid further vision loss.

7 Oct 2011

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.

4 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011